Danaher’s (DHR) “Buy” Rating Reiterated at Robert W. Baird
Danaher (NYSE:DHR)‘s stock had its “buy” rating reiterated by stock analysts at Robert W. Baird in a research report issued to clients and investors on Friday.
Several other research analysts have also recently issued reports on DHR. Goldman Sachs Group restated a “neutral” rating and issued a $83.00 price objective on shares of Danaher in a research note on Tuesday, September 26th. Evercore ISI began coverage on Danaher in a research report on Wednesday, January 3rd. They set an “outperform” rating for the company. Royal Bank of Canada reiterated a “hold” rating and set a $96.00 price target on shares of Danaher in a research report on Thursday, January 4th. Cowen reiterated a “buy” rating and set a $90.00 price target on shares of Danaher in a research report on Wednesday, October 4th. Finally, Citigroup lifted their price target on Danaher to $107.00 and gave the company a “buy” rating in a research report on Friday, December 15th. One analyst has rated the stock with a sell rating, six have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Danaher has an average rating of “Buy” and a consensus price target of $94.91.
Shares of Danaher (NYSE:DHR) traded up $0.80 during trading hours on Friday, hitting $99.39. The stock had a trading volume of 1,875,557 shares, compared to its average volume of 2,137,105. Danaher has a 1 year low of $78.97 and a 1 year high of $99.66. The stock has a market capitalization of $69,136.18, a PE ratio of 29.32, a price-to-earnings-growth ratio of 2.15 and a beta of 1.02. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43.
In other news, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $92.64, for a total value of $11,671,620.96. Following the completion of the sale, the chief executive officer now directly owns 271,737 shares in the company, valued at $25,173,715.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total value of $3,534,407.10. The disclosure for this sale can be found here. Insiders sold 273,810 shares of company stock valued at $25,218,813 over the last 90 days. Company insiders own 12.20% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. GQG Partners LLC purchased a new stake in shares of Danaher in the second quarter valued at approximately $101,000. Zions Bancorporation boosted its stake in shares of Danaher by 118.3% in the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after acquiring an additional 667 shares during the last quarter. Patten Group Inc. boosted its stake in shares of Danaher by 262.3% in the third quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after acquiring an additional 3,497 shares during the last quarter. Monetary Management Group Inc. boosted its stake in shares of Danaher by 10.7% in the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after acquiring an additional 150 shares during the last quarter. Finally, Acrospire Investment Management LLC boosted its stake in shares of Danaher by 185.5% in the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after acquiring an additional 1,100 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/14/danahers-dhr-buy-rating-reiterated-at-robert-w-baird.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.